Application of Infliximab in treating of severe polyarticular juvenile idiopathic arthritis
10.3760/cma.j.issn.2095-428X.2013.03.017
- VernacularTitle:英夫利西单抗在重症多关节炎型幼年特发性关节炎中的应用
- Author:
Min KANG
1
;
Feng-Qi WU
;
Gai-Xiu SU
;
Zhi-Xuan ZHOU
;
Ying-Jie XU
Author Information
1. 100020,首都儿科研究所附属儿童医院风湿免疫科
- Keywords:
Infliximab;
Idiopathic arthritis;
Juvenile;
Polyarticular;
Safety;
Efficacy
- From:
Chinese Journal of Applied Clinical Pediatrics
2013;28(3):217-219
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the safety and efficacy of infliximab in the treatment of severe polyarticular juvenile idiopathic arthritis(JIA).Methods Forty-four patients with severe polyarticular JIA were treated with infliximab (3 mg/kg) on week 0,2 and 6,respectively,and then they were treated every 8 weeks,plus methotrexate or and leflunomide for oral intake,and meanwhile physical therapy and functional rehabilitation were carried out.Patients were assessed by the American College of Rheumatology (ACR) response criteria (30,50,70) on week 2,6 and 14 and followed up,including swollen joint count,tender joint count,duration of morning stiffness and fever,body functions,lab inflammatory index like CRP,ESR changes.Results Among 44 cases,according to ACR response criteria,which represents 30％,50％,70％ improvement from baseline,the cure rates with infliximab therapy in swollen joint count,tender joint count,duration of morning stiffness,CRP,ESR were achieved in 47.7％ (21/44 cases),20.5％ (9/44 cases),and 11.4％ (5/44 cases) of patients with JIA on week 2 ; 63.6％ (28/44 cases),43.2％ (19/44 cases),and 13.6％ (6/44 cases) of patients on week 6 ;81.8％ (36/44 cases),52.2％ (23/44 cases),27.2％ (12/44 cases) on week 14,respectively.Inflammatory index like CRP,ESR with infliximab treatment decreased considerably compared that before treatment(P ＜0.05).Side effects from infliximab treatment were well-tolerated.There was no abnormality in the liver and kidneys or complicated infections,and no negative cases turned into the positive.Conclusions Treating severe polyarticular JIA with infliximab showed a rapid cure rate,safety and better tolerance.
